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Summary
Background Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to 
cohorts from Europe and the USA, with few data from low-income and middle-income countries. We therefore aimed 
to describe the characteristics, severity of disease, microbiology, and treatment of patients with bronchiectasis in India.
Methods The Indian bronchiectasis registry is a multicentre, prospective, observational cohort study. Adult patients 
(≥18 years) with CT-confirmed bronchiectasis were enrolled from 31 centres across India. Patients with bronchiectasis due 
to cystic fibrosis or traction bronchiectasis associated with another respiratory disorder were excluded. Data were collected 
at baseline (recruitment) with follow-up visits taking place once per year. Comprehensive clinical data were collected 
through the European Multicentre Bronchiectasis Audit and Research Collaboration registry platform. Underlying 
aetiology of bronchiectasis, as well as treatment and risk factors for bronchiectasis were analysed in the Indian 
bronchiectasis registry. Comparisons of demographics were made with published European and US registries, and quality 
of care was benchmarked against the 2017 European Respiratory Society guidelines.
Findings From June 1, 2015, to Sept 1, 2017, 2195 patients were enrolled. Marked differences were observed between 
India, Europe, and the USA. Patients in India were younger (median age 56 years [IQR 41–66] vs the European and 
US registries; p<0∙0001]) and more likely to be men (1249 [56∙9%] of 2195). Previous tuberculosis (780 [35∙5%] of 
2195) was the most frequent underlying cause of bronchiectasis and Pseudomonas aeruginosa was the most common 
organism in sputum culture (301 [13∙7%]) in India. Risk factors for exacerbations included being of the male sex 
(adjusted incidence rate ratio 1∙17, 95% CI 1∙03–1∙32; p=0∙015), P aeruginosa infection (1∙29, 1∙10–1∙50; p=0∙001), a 
history of pulmonary tuberculosis (1∙20, 1∙07–1∙34; p=0∙002), modified Medical Research Council Dyspnoea score 
(1∙32, 1∙25–1∙39; p<0∙0001), daily sputum production (1∙16, 1∙03–1∙30; p=0∙013), and radiological severity of disease 
(1∙03, 1∙01–1∙04; p<0∙0001). Low adherence to guideline-recommended care was observed; only 388 patients were 
tested for allergic bronchopulmonary aspergillosis and 82 patients had been tested for immunoglobulins.
Interpretation Patients with bronchiectasis in India have more severe disease and have distinct characteristics from 
those reported in other countries. This study provides a benchmark to improve quality of care for patients with 
bronchiectasis in India.
Funding EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative 
inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis Consortium, European Respiratory Society, and the British 
Lung Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Bronchiectasis is a growing global health problem. In 
Europe and the USA the reported prevalence of the disease 
has increased by more than 40% in the past 10 years.1 
Although substantial progress has occurred in under­
standing the epidemiology of bronchiectasis, large­scale 
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epidemiological data have been almost exclusively from 
European countries, the USA, and Australia.2,3 Small 
cohorts from China and South America suggest that the 
characteristics of patients from low­income and middle­
income countries might be different to those in Europe.4,5 
Patients with bronchiectasis in high­income countries are 
predominantly older and female, and approximately 
40% are idio pathic.2,3 The demographics, microbiology, 
severity of disease, and clinical phenotypes of bronchiec­
tasis in low­income and middle­income countries such as 
India are not well described.
Understanding the heterogeneity of disease is currently 
the key research priority in bronchiectasis.6,7 Several 
international randomised trials have not been able to meet 
their primary endpoints. It is speculated that this outcome 
is because different patients with bronchiectasis have 
different characteristics and treatment responses.8–10 Most 
recently the RESPIRE programme10 tested inhaled dry 
powder ciprofloxacin in patients with bronchiectasis and 
achieved positive results in RESPIRE­1,8 which was done 
predominantly in Europe and the USA, but not in 
RESPIRE­2,9 which was done predominantly in eastern 
Europe and Asia.8–10 Multicentre randomised controlled 
trials have frequently taken place in low­income and 
middle­income countries where the characteristics of 
patients are not well understood. In Asia, tuberculosis 
is thought to be an important underlying cause of 
bronchiectasis.11 Studies systematically doing CT in 
patients following treatment for tuberculosis have 
identified moderate or severe bronchiectasis in approxi­
mately 40% of patients, but data for the symptoms, lung 
function impairment, health­care resource utilisation, and 
treatment of these patients remain scarce.12,13
The European Multicentre Bronchiectasis Audit and 
Research Collaboration (EMBARC) was established in 
2012 through the European Respiratory Society (ERS) to 
facilitate research in bronchiectasis across Europe.14 
In 2014, the EMBARC network partnered with the 
Respiratory Research Network of India to establish 
an Indian bronchiectasis registry. To our knowledge, 
this partnership is the first prospective multicentre 
bronchiectasis registry to be established in a lower­
middle­income country. Herein, we report the first 
results of the Indian national bronchiectasis registry 
describing the clinical characteristics, severity of disease, 
and clinical phenotypes of bronchiectasis in India.
Methods
Study design and participants
The Indian bronchiectasis registry is a multicentre, 
prospective, observational cohort study. It is a non­
interventional study, enrolling adult patients with 
Research in context
Evidence before this study
Bronchiectasis is a chronic respiratory disease causing cough, 
sputum production, and frequent chest infections leading to 
poor quality of life and high health-care resource utilisation. It 
is a frequent consequence of pulmonary tuberculosis 
infection, with a systematic review suggesting about 40% of 
survivors of tuberculosis infection develop radiological 
bronchiectasis. A recent published systematic review of 
MEDLINE from inception to 2018 for studies of the 
epidemiology and natural history of bronchiectasis identified 
that bronchiectasis is a common respiratory disease 
worldwide, affecting up to 566 per 100 000 population in 
high-income countries. Little published data are available 
from Asia, Africa, South America, or from low-income and 
middle-income countries more generally. The little data that 
are available suggest there might be considerable 
geographical variation in patient characteristics and 
management. However, no data for the burden of 
bronchiectasis in India exist. Disease registries can provide 
useful data for the epidemiology of disease.
Added value of this study
We developed a patient registry across 31 centres in India 
collecting comprehensive data for patient demographics, severity 
of disease, comorbidities, microbiology, and current treatment. 
Patients with bronchiectasis in India show marked differences to 
those previously reported in Europe and the USA. Patients in India 
were younger, more likely to be men, and showed a high 
frequency of severe, cystic bronchiectasis. Tuberculosis and other 
severe infections were the most frequently reported underlying 
cause. Indian patients had a high burden of symptoms and a high 
frequency of hospital admission for severe worsening of disease 
known as exacerbations. Patients were frequently and chronically 
infected with bacteria such as Pseudomonas aeruginosa. Markers of 
quality of care suggested that many patients in India do not 
currently receive evidence-based low-cost interventions such as 
chest physiotherapy. Previous tuberculosis infection was a risk 
factor for exacerbations.
Implications of all the available evidence
We identify risk factors for exacerbations and suggest areas for 
improvement in the care of bronchiectasis in India. Our study 
highlights the high severity and symptom burden associated with 
bronchiectasis in India and this is likely to be replicated in similar 
countries with a high prevalence of tuberculosis and severe 
respiratory infections. Bronchiectasis is a neglected disease and 
our data suggest a need for efforts to improve access to basic care 
interventions for bronchiectasis such as chest physiotherapy, 
vaccinations, and antibiotics. The discordance between patient 
characteristics in India compared with Europe and the USA 
suggest that data from high-income countries might not be 
generalisable to India and other Asian countries. There is a need 
to do interventional studies to demonstrate improvements in 
clinical outcomes specifically in Asian countries.
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bronchiectasis across the country at 31 participating 
centres. Figure 1 shows the various participating sites 
across India. Patients fulfilling the inclusion criteria 
(aged ≥18 years with bronchiectasis on CT of the chest 
and the clinical syndrome of bronchiectasis defined by 
the presence of cough, sputum production, or recurrent 
respiratory infections) and not the exclusion criteria 
(inability to give informed consent, bronchiectasis due to 
cystic fibrosis, and traction bronchiectasis associated 
with interstitial lung disease or another respiratory 
disorder) were enrolled. The study was approved by the 
institution review boards of the participating centres. 
Patients gave written informed consent to participate in 
this study.
Assessments
Data were collected at baseline (recruitment) with 
follow­up visits taking place once per year. During 
the baseline and follow­up visits, comprehensive data 
were collected across various domains, including 
demographics, comorbidities, laboratory testing, lung 
function, exacerbations, disease impact, microbiology, 
radiology, and treatment and physiotherapy.
Lung function testing was done according to the ERS 
and American Thoracic Society technical standards 
and percentage of predicted forced expiratory volume in 
1 s (FEV1) calculated using reference values for south 
Asian patients.15 Airflow obstruction was defined by an 
FEV1/forced vital capacity (FVC) ratio of less than 0∙7. True 
airflow restriction cannot be identified without total lung 
capacity, which was not measured in the study. Patients 
with an FEV1/FVC ratio of 0∙7 or more and an FEV1 and 
FVC of less than 80% of predicted values were therefore 
classified as spirometric restriction as previously described 
in an African population.16 Breathlessness was evaluated 
using the modified Medical Research Council Dyspnoea 
(mMRCD) scale. Quality of life was assessed using the 
Quality of Life Bronchiectasis Questionnaire (version 3.1) 
in a subset of patients in English because of the absence of 
a validated translation in India.17 CT scans were scored 
using the modified Reiff score (appendix p 1).18
The aetiology of bronchiectasis was recorded as 
determined by the treating physician. All objective tests 
and comorbidities were recorded in order to validate the 
quality of the aetiological diagnosis. Allergic broncho­
pulmonary aspergillosis was diagnosed according to 
consensus guidelines.19 Treatable diagnoses were those 
referred to in the European bronchiectasis guidelines such 
as immunodeficiency, allergic bronchopulmonary asper­
gillosis, and non­tuberculous mycobacterial infection.19
No Indian guidelines for management of bronchiec­
tasis exist, and the only international guidelines published 
are from the ERS in 2017.20 These international guidelines 
provided a series of recommendations for management 
based on nine domains covering diagnosis of the 
underlying cause of bronchiectasis and treatment.20 
To assess quality of care, we extracted guideline 
recommendations and tested within our dataset whether 
patients were managed according to these recom­
mendations. The selected quality standards were 
aetiological diagnosis (patients should be tested for 
allergic bronchopulmonary aspergillosis and have 
immunoglobulins measured), eradication (patients with 
new Pseudomonas aeruginosa infection should have an 
attempt at eradication), long­term antibiotics (patients 
with ≥3 exacerbations per year should be treated with oral 
or inhaled antibiotics), bronchodilators (patients with 
significant breathlessness should be prescribed long­
acting bronchodilators), and respiratory physiotherapy 
(patients should be taught how to do airway clearance 
techniques and patients with significant breathlessness 
should be referred to pulmonary rehabilitation). Patients 
with spontaneous sputum production should have 
sputum sent at least once per year for bacterial culture. To 
reflect the reality that there are often good clinical reasons 
not to follow guidelines in some cases, we used a 
threshold of 80% to indicate compliance with guideline­
based care.21
Comparison with European and US data
To allow demographics and disease burden characteristics 
to be compared with international data, we did 
comparisons of the Indian registry data with equivalent 
data from the published FRIENDS substudy of the 
European registry (which included data from Israel) and 
from the US bronchiectasis registry.2,3 The Indian registry 
was designed to utilise identical definitions and data 
fields as the European registry, which in turn was 
designed to mirror data from the US registry.
Statistical analysis
We presented categorical variables as frequencies and 
percentages, and analysed statistical differences using a 
χ² test or Fisher’s exact test when required. We presented 
continuous variables as mean and SD, or median and 
interquartile range (IQR) when data were not distributed 
normally. Frequency of exacerbations and hospital 
admissions during the study were analysed with a 
negative binomial model with time in study as an offset. 
We presented results as incidence rate ratios (IRRs) with 
corresponding 95% CIs.
We used logistic regression to calculate adjusted odds 
ratios (aORs) for categorical outcome variables. In 
multivariable models, we selected clinically relevant 
confounder variables using published models for 
exacerbation frequency in bronchiectasis as a guide.22 
Further details of the models are shown in the appendix 
(p 1). We defined statistical significance as a two­tailed 
p≤0∙05.
We did the statistical analyses using SPSS (version 22.0).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
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Results
From June 1, 2015, to Sept 1, 2017, 2195 patients were 
enrolled consecutively from 31 centres across India. 
The median number of patients enrolled per centre 
was 58 (IQR 24–113), with the largest centre recruiting 
304 patients. Ten (32%) of 31 centres would be regarded 
as tertiary referral centres and 21 (68%) as secondary care 
respiratory clinics. Most hospitals served predominantly 
urban populations (appendix pp 1–3). Patients had a 
median age of 56 years (IQR 41–66); and of the 
2195 patients, 1249 (56∙9%) were men and 1576 (71∙8%) 
never smoked.
Figure 2 shows the frequency of reported aetiologies. The 
most frequent cause was tuberculosis (780 [35∙5%] of 
2195 patients), followed by a post­infection (491 [22∙4%]), 
and idiopathic bronchiectasis (470 [21∙4%]). Allergic 
broncho pulmonary aspergillosis was also highly prevalent 
as a cause of bronchiectasis, with 196 (8∙9%) of 
2195 patients. Less common causes were chronic 
obstructive pulmonary disease (COPD; 116 [5∙3%]), 
asthma (54 [2∙5%]), rheuma toid arthritis (40 [1∙8%]), and 
primary ciliary dyskinesia (18 [<1%]). Non­tuberculous 
mycobacteria, gastro­oesophageal reflux disease, immuno­
deficiency, α­1 anti­trypsin deficiency, and tracheo­
bronchomegaly were also represented (figure 2).
Treatable causes, as defined by the ERS, were identified 
in 232 (10∙6%) of 2195 patients and this number 
increased to 571 (26%) in centres where specific IgE to 
Aspergillus fumigatus and immunoglobulins were tested 
routinely. Among those where the bronchiectasis was 
attributed to a previous infection other than tuberculosis, 
the most frequently reported infections were pneu­
monia in 351 (71∙5%) of 491 patients, other childhood 
respiratory infections in 143 (29∙1%) patients, and 
pertussis in nine (1∙8%) patients. The total adds up to 
more than 491, as some patients had more than one type 
of previous infection. Among patients with allergic 
broncho pulmonary aspergillosis, 42 (21∙4%) of 196 were 
currently treated with oral corticosteroids and 18 (9∙2%) 
were receiving anti­fungal medications at baseline. Of 
388 patients tested for allergic bronchopulmonary 
aspergillosis, the diagnosis was made in 191 (49∙2%).
Overall, 916 (41∙7%) of 2195 patients had a history of 
pulmonary tuberculosis. 34 (3∙7%) of 916 patients were 
receiving treatment for active pulmonary tuberculosis at 
the time of enrolment. 25 (2∙7%) were culture positive 
for Mycobacterium tuberculosis at the time of enrolment.
Figure 3 shows the distribution of bronchiectasis 
according to the lobes affected, showing a relatively equal 
distribution between bronchiectasis affecting the upper, 
middle, and lower lobes. Cystic dilatation was the dominant 
radiological pattern. Despite this radiological severity, the 
majority of the patients (1284 [58∙5%] of 2195) did not 
report production of daily sputum. The appendix (pp 3–4) 
shows clinical factors associated with sputum production. 
Patients with more severe disease, P aeruginosa infection, 
and cystic dilatation on CT were more likely to be sputum 
producers. Currently macrolide use was associated with 
lack of  sputum production (appendix pp 3–4).
Figure 1: Location of participating sites in the Indian bronchiectasis registry
Figure 2: Underlying causes of bronchiectasis in the Indian bronchiectasis 
registry
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The mean frequency of all exacerbations inluding severe 
was 1∙15 per year (SD 1∙5) and the mean frequency of 
severe exacerbations requiring hospital admission was 
0∙55 per year (SD 0∙9). Using the bronchiectasis severity 
index score, we observed 728 (33∙2%) of 2195 with mild 
bronchiectasis, 674 (30∙7%) with moderate bronchiec­
tasis, and 793 (36∙1%) with severe bronchiectasis 
(figure 3F). The frequent exacerbator phenotype 
(≥3 per year) was seen in 529 (24∙1%) of 2195 patients. A 
comparison of characteristics of frequent and infrequent 
exacerbators is shown in the appendix (pp 4–6).
Breathlessness was a common symptom among the 
participants. 169 (7∙7%) of 2195 patients had an mMRCD 
grade 4, 394 (17∙9%) had an mMRCD grade 3, 
638 (29∙1%) reported a grade 2, 646 (29∙4%) a grade 1, 
and 348 (15∙9%) a grade 0. Breathlessness, daily sputum 
production, exacerbations, and chronic airway infection 
were independently associated with worse quality of life 
scores in linear regression models suggesting these 
factors are the major drivers of poor quality of life in 
Indian patients with bronchiectasis (appendix pp 3–4).
In terms of the severity of FEV1 impairment, the overall 
median FEV1 was 1∙31 L (IQR 0∙88–1∙84), which 
translated to a median predicted percentage of 61∙4% 
(IQR 41∙9–80∙5). Airflow obstruction was the pre­
dominant spirometric abnormality affecting 764 (34∙8%) 
of 2195 patients. Low FVC (defined as spirometric 
restriction) was, however, surprisingly common, 
affecting 585 (26∙7%) of 2195 patients. Of the 764 patients 
with airflow obstruction, 706 (92∙4%) had fixed airflow 
obstruction on post­bronchodilator spirometry. Pre­
broncho dilator spirometry only was available for the 
other 58 (7∙6%) participants.
We did a logistic regression model to identify variables 
associated with this low FVC phenotype and identified a 
strong association with post­tuberculosis bronchiectasis 
(aOR 2∙02, 95% CI 1∙45–2∙82; p<0∙0001; appendix pp 6–7).
1299 (59∙2%) of 2195 patients had at least one sputum 
sample taken in the year before the baseline visit. The 
most frequent isolated organism was P aeruginosa in 
301 (13∙7%) patients, followed by Enterobacteriaceae 
species (215 [9∙8%]) such as Escherichia and Klebsiella 
pneumoniae. Acinetobacter sp was isolated in 22 (1∙0%) 
patients. Organisms commonly reported in western 
Europe and US cohorts such as Haemophilus influenzae 
(11 [0∙5%] of 2195 patients), Moraxella catarrhalis 
(22 [1∙0%]), Streptococcus pneumoniae (18 [0∙8%]), 
Staphylococcus aureus (50 [2∙3%]), and non­tuberculous 
mycobacteria (eight [0∙4%]) were uncommon in the 
participants.
Figure 4 shows the most commonly prescribed 
treatments. These treatments included inhaled 
Figure 3: Extent and severity of bronchiectasis in the Indian bronchiectasis registry
(A) Radiological distribution of bronchiectasis. Percentages refer to the lobes affected with the lingula treated as a separate lobe. Percentages add up to more than 
100% as patients can have multiple lobes affected. (B) Dominant radiological pattern on CT. (C) Spirometry pattern at baseline. Low FVC was defined as spirometric 
restriction; obstruction was defined by FEV1/FVC <0∙7 and normal spirometry required an FEV1 and FVC above 80% of predicted value. (D) Number of exacerbations 
treated with oral antibiotics. (E) Number of exacerbations requiring admission to a hospital. (F) Distribution of the multidimensional Bronchiectasis Severity Index. 
FEV1 /FVC=ratio of forced expiratory volume in 1 s/forced vital capacity.
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bronchodilators, long­term antibiotics, mucoactive drugs, 
and chest physiotherapy. 1387 (63∙2%) of 2195 patients 
were receiving inhaled corticosteroids, and in 1242 
(56∙6%) of patients this treatment was a fixed combination 
of an inhaled corticosteroid with a long­acting β agonist. 
N­acetylcysteine was the most commonly used 
mucoactive drug. Drugs such as theophylline, leukotriene 
receptor antagonists, and bronchodilators were frequently 
used in patients without a history of asthma or COPD.
Long­term antibiotics were infrequently used, with the 
most common regimens being a rotating long­term 
antibiotic regimen—eg, targeted oral antibiotics for 
several months of the year (195 [8∙9%] of 2195 patients) 
and long­term oral antibiotics other than macrolide 
(136 [6∙2%]), which include long­term amoxicillin­
clavulanic acid (70 [3∙2%]), fluoroquinolones (25 [1∙1%]), 
and tetracyclines (17 [1∙0%]).
Using the ERS guideline recommendations as a 
benchmark, we observed low adherence to guideline­
recommended care.21 Only 388 patients were tested for 
allergic bronchopulmonary aspergillosis and 82 patients 
had been tested for immunoglobulins. Consequently, only 
67 (3∙1%) of 2195 patients were tested according to the ERS 
guideline recommendations. Among 306 patients with a 
history of P aeruginosa infection, eradication had been 
attempted in 207 (67∙6%) patients. Out of 529 patients 
with three or more exacerbations per year, 351 (66∙4%) 
patients were receiving no prophylactic therapy.
1201 patients had an mMRCD score of 2 or more. Of 
these patients, 315 (26∙2%) patients were not receiv­
ing any long­acting bronchodilators. 927 (42∙2%) of 
2195 patients with bronchiectasis in India had received 
training in airway clearance. 515 (40∙4%) of 1274 patients 
who complained of daily sputum production had been 
trained in airway clearance techniques. After excluding 
patients that were not suitable for pulmonary 
rehabilitation because of comorbidities and those who 
declined to attend, 932 patients had an mMRCD score 
of 2 or more and would be eligible for referral to 
pulmonary rehabilitation, of which 355 (38∙1%) patients 
had attended pulmonary rehabilitation. Figure 4D 
summarises the data and indicates that currently none 
of these domains achieve the 80% target for quality 
standard adherence.
Differences in patient characteristics were observed 
according to underlying aetiology and other disease 
characteristics. Table 1 shows a comparison of patient 
characteristics according to the underlying aetiology 
assigned by the treating clinician. Comparing these 
groups, patients with asthma and allergic broncho­
pulmonary aspergillosis were younger than other 
subgroups, and patients with COPD were more likely 
to be men. Post­tuberculosis bronchiectasis showed 
characteristics in terms of severity, microbiology, and 
demographics that were similar to idiopathic and post­
infective disease. Patients with overlapping bronchiectasis 
and COPD tended to have more severe disease.
Other key phenotypes other than those associated with 
aetiology, include the so­called frequent exacerbator 
and P aeruginosa infection as a distinct phenotype.22 
Examining the frequent exacerbator phenotype in the 
Indian registry, exacerbations during follow­up were 
most strongly associated with men (adjusted IRR 1∙17, 
95% CI 1∙03–1∙32; p=0∙015), P aeruginosa infection 
(1∙29, 1∙10–1∙50; p=0∙001), a history of pulmonary 
tuberculosis (1∙20, 1∙07–1∙34; p=0∙002), mMRCD score 
(1∙32, 1∙25–1∙39; p<0∙0001), daily sputum production 
(1∙16, 1∙03–1∙30; p=0∙013), and radiological severity 
Figure 4: Most commonly prescribed treatments for bronchiectasis and the quality-of-care indicators in the Indian bronchiectasis registry
(A) Bronchodilators and inhaled treatments. (B) Airway clearance and mucoactive drugs. (C) Long-term antibiotic therapy. (D) Quality standards for bronchiectasis 
management in India. The numbers indicate the number of patients eligible. ICS=inhaled corticosteroids. LABA=long-acting β agonist. LAMA=long-acting muscarinic 
antagonist. LTRA=leukotriene receptor antagonist. *Includes ICS in combination with LABA, ICS monotherapy, and ICS, LABA, and LAMA in a single inhaler.
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Post-tuberculosis 
(n=780)
Idiopathic 
(n=469)
Post-infective 
(non-tuberculosis; 
n=491)
Allergic 
bronchopulmonary 
aspergillosis (n=196)
Chronic 
obstructive 
pulmonary 
disease (n=116)
Asthma (n=54) Other (n=89)
Demographics 
Age (years) 57 (44–67) 56 (43–66) 53 (39–64) 46 (33–57) 64 (56–70) 52 (45–62) 56 (39–63)
Men 465 (59∙6%) 265 (56∙5%) 270 (55∙0%) 102 (52∙0%) 84 (72∙4%) 23 (42∙6%) 40 (44∙9%)
Body-mass index 21∙0 (18∙1–23∙8) 22∙2 (19∙0–25∙3) 21∙6 (18∙7–24∙4) 21∙6 (18∙8–24∙9) 22∙6 (19∙4–26∙4) 24∙0 (22∙3–26∙0) 20∙9 (17∙3–24∙0)
Ex-smokers 223 (28∙6%) 78 (16∙6%) 110 (22∙4%) 16 (8∙2%) 56 (48∙3%) 8 (14∙8%) 15 (16∙9%)
Current smokers 61 (7∙8%) 18 (3∙8%) 12 (2∙4%) 3 (1∙5%) 16 (13∙8%) 2 (3∙7%) 1 (1∙1%)
Comorbidity
Ischaemic heart disease 97 (12∙4%) 92 (19∙6%) 64 (13∙0%) 25 (12∙8%) 36 (31∙0%) 20 (37∙0%) 21 (23∙6%)
Stroke 6 (0∙8%) 0 3 (0∙6%) 0 0 0 0
Diabetes 122 (15∙6%) 67 (14∙3%) 61 (12∙4%) 11 (5∙6%) 37 (31∙9%) 9 (16∙7%) 8 (9∙0%)
Liver disease 13 (1∙7%) 3 (0∙6%) 2 (0∙4%) 0 0 0 0
Chronic renal failure 9 (1∙2%) 4 (0∙9%) 5 (1∙0%) 2 (1∙0%) 3 (2∙6%) 0 1 (1∙1%)
Chronic obstructive pulmonary disease 213 (27∙3%) 75 (16∙0%) 85 (17∙3%) 11 (5∙6%) NA 0 15 (16∙9%)
Asthma 79 (10∙1%) 91 (19∙4%) 81 (16∙5%) 158 (80∙6%) 8 (6∙9%) NA 12 (13∙5%)
Osteoporosis 56 (7∙2%) 8 (1∙7%) 29 (5∙9%) 11 (5∙6%) 13 (11∙2%) 7 (13∙0%) 6 (6∙7%)
Gastro-oesophageal reflux disease 140 (17∙9%) 45 (9∙6%) 100 (20∙4%) 18 (9∙2%) 20 (17∙2%) 4 (7∙4%) 19 (21∙3%)
Solid tumour 7 (0∙9%) 3 (0∙6%) 4 (0∙8%) 0 2 (1∙7%) 0 1 (1∙1%)
Disease severity
BSI score 7 (4–10) 6 (3–9) 7 (4–10) 5 (2–9) 9 (5–12) 6 (3–9) 8 (5–12)
BSI score risk class
Mild 241 (30∙9%) 173 (36∙9%) 157 (32∙0%) 97 (49∙5%) 19 (16∙4%) 22 (40∙7%) 19 (21∙3%)
Moderate 230 (29∙5%) 158 (33∙7%) 162 (33∙0%) 46 (23∙5%) 36 (31∙0%) 14 (25∙9%) 28 (31∙5%)
Severe 309 (39∙6%) 138 (29∙4%) 172 (35∙0%) 53 (27∙0%) 61 (52∙6%) 18 (33∙3%) 42 (47∙2%)
Radiological status
Reiff score 6 (3–9) 6 (3–9) 6 (3–9) 6 (5–12) 6 (3–9) 6 (2–9) 6 (4–9)
Cystic dilatation 436 (55∙9%) 289 (61∙6%) 362 (73∙7%) 141 (71∙9%) 80 (69∙0%) 28 (51∙9%) 54 (60∙7%)
Clinical status
Sputum volume (mL/day) 10 (0–30) 5 (0–30) 10 (0–30) 5 (0–20) 20 (5–40) 10 (0–30) 10 (0–28)
Modified Medical Research Council 
Dyspnoea score
2 (1–3) 1 (1–2) 2 (1–3) 1 (0–2) 2 (2–3) 2 (1–3) 2 (1–3)
Exacerbations in the previous year 1 (0–3) 1 (0–2) 1 (0–3) 1 (0–2) 1 (0–2) 1 (0–2) 2 (1–3)
≥1 hospital admission in the previous year 335 (42∙9%) 213 (45∙4%) 171 (34∙8%) 57 (29∙1%) 63 (54∙3%) 21 (38∙9%) 42 (47∙2%)
Functional status
FEV1 (% predicted) 63∙9 (46∙9–79∙9) 58∙7 (38∙6–79∙3) 52∙8 (36∙5–70∙0) 55∙4 (39∙7–77∙4) 47∙8 (35∙9–79∙2) 63∙2 (46∙4–80∙1) 60∙6 (36∙5–85∙4)
Microbiology
Pseudomonas aeruginosa 105 (13∙5%) 66 (14∙1%) 67 (13∙6%) 19 (9∙7%) 19 (16∙4%) 5 (9∙3%) 20 (22∙5%)
Haemophilus influenzae 1 (0∙1%) 6 (1∙3%) 3 (0∙6%) 0 0 1 (1∙9%) 0
Staphylococcus aureus 34 (4∙4%) 5 (1∙1%) 10 (2∙0%) 0 1 (0∙9%) 0 0
Moraxella catarrhalis 7 (0∙9%) 6 (1∙3%) 8 (1∙6%) 1 (0∙5%) 0 0 0
Enterobacteriaceae 81 (10∙4%) 43 (9∙2%) 43 (8∙8%) 13 (6∙6%) 16 (13∙8%) 8 (14∙8%) 11 (12∙4%)
Treatment 
Long-term macrolide treatment 51 (6∙5%) 15 (3∙2%) 47 (9∙6%) 4 (2∙0%) 9 (6∙9%) 2 (3∙7%) 7 (7∙9%)
Other long-term oral antibiotic treatments 54 (6∙5%) 20 (4∙3%) 46 (9∙4%) 7 (3∙6%) 3 (2∙6%) 0 7 (7∙9%)
Inhaled antibiotic treatment 14 (1∙8%) 10 (2∙1%) 20 (4∙1%) 19 (9∙7%) 9 (7∙8%) 3 (5∙6%) 4 (4∙5%)
Quality of life 
Quality-of-life bronchiectasis questionnaire 
(Respiratory Symptom Score)
66∙7 (44∙4–77∙8) 59∙3 (38∙1–81∙5) 63∙0 (51∙9–70∙4) 66∙7 (55∙6–85∙2) 57∙5 (41∙6–66∙7) 63∙0 (37∙0–69∙0) 51∙9 (19∙0–66∙7)
Data are median (IQR) or n (%). BSI=Bronchiectasis Severity Index. FEV1=forced expiratory volume in 1 s. NA=not applicable.
Table 1: Characteristics and severity of disease in patients according to the underlying aetiology assigned by the clinician
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of disease (1∙03, 1∙01–1∙04; p<0∙0001). Macrolide treat­
ment was also associated with a higher frequency of 
exacerbations (adjusted IRR 1∙48, 95% CI 1∙19–1∙83; 
p<0∙0001). The appendix (pp 8–9) shows the full results 
of the model and the determinants of poor quality of life.
2596 patients from Europe and Israel were included. 
We refer to this comparative group as Europe for brevity, 
and the 2596 patients were compared with the cohort of 
patients from India (table 2). Significant differences were 
observed in the majority of demographic, comorbidity, 
disease severity, radiological, clinical, functional status, 
and microbiological domains. Indian patients were 
younger, more likely to be men, and had a lower body­
mass index (BMI) than their European counterparts. 
Consistent with a younger age, there were less 
comorbidities, except for a higher incidence of diabetes. 
Indian patients were more likely to be classified as severe 
using the Bronchiectasis Severity Index and had more 
extensive, cystic, radiological disease. Outpatient exacer­
bations were less common but hospitalised exacerbations 
were more common in India than in Europe. FEV1 
percentage predicted was lower in Indian patients than 
in European patients. Both long­term oral and inhaled 
antibiotic treatments were more commonly used in 
Europe than in India (table 2).
In a negative binomial model, Indian patients were 
more likely to be admitted to hospital during the study 
than European patients (adjusted IRR 1∙21, 95% CI 
1∙04–1∙40; p=0∙011) but had a lower frequency of reported 
outpatient exacerbations (0∙60, 0∙55–0∙66; p<0∙0001).
Long­term oral antibiotic prophylaxis was less frequently 
used in India than in Europe (OR 0∙58, 95% CI 0∙44–0∙68; 
p<0∙0001), a difference that persisted after adjustment for 
patient characteristics (aOR 0∙80, 95% CI 0∙65–0∙98; 
p=0∙03). Patients in India were less likely to receive 
inhaled antibiotics than in Europe (OR 0∙58, 95% CI 
0∙44–0∙77; p<0∙0001) but this result was not significant in 
the multivariate analysis (aOR 0∙78, 95% CI 0∙52–1∙16; 
p=0∙26).
Data from patients in the Indian registry were 
compared with published data from the US registry 
(n=1826). The patients from the US registry had a mean 
age of 64 years (SD 14). 721 (39∙7%) of 1815 were current 
or former smokers, with a mean BMI of 23∙2 (SD 5∙7). 
Compared with these values, Indian patients were 
significantly younger, less likely to have a smoking 
history, and had a lower BMI. In terms of microbiology, 
470 (33∙4%) of 1406 of the US registry participants had 
at least one isolation of P aeruginosa while other patho­
gens included S aureus (170 [12∙1%]), H influenzae 
(116 [8∙3%]) and non­tuberculous mycobacterial infec­
tion (657 [50∙0%] of 1314). Indian patients therefore had 
a significantly lower isolation of P aeruginosa and non­
tuberculous mycobacterial infection (both p<0∙0001). 
Oral antibiotic prophylaxis was used in 125 (7∙1%) of the 
US registry participants, and inhaled antibiotics were 
used in 178 (10∙1%). Indian patients were therefore more 
likely to receive oral antibiotic prophylaxis than those in 
the US registry but were less likely to receive inhaled 
antibiotics. A comparison of microbiology in the Indian, 
European, and US registries is shown in the appendix 
(pp 9–10).
Discussion
This study is, to our knowledge, the first large­scale 
registry study of patients with adult bronchiectasis done 
India (n=2195) Europe* (n=2596) p value
Demographics 
Age (years) 56 (41–66) 67 (57–74) <0∙0001
Men 1249 (56∙9%) 1010 (38∙9%) <0∙0001
Body-mass index 21∙5 (18∙5–24∙5) 24∙8 (21∙8–28∙1) <0∙0001
Current or former smokers 619 (28∙2%) 990 (38∙1%) <0∙0001
Comorbidity
Ischaemic heart disease 355 (16∙2%) 453 (17∙5%) 0∙2
Stroke 9 (0∙4%) 152 (5∙9%) <0∙0001
Diabetes 315 (14∙4%) 260 (10∙0%) <0∙0001
Liver disease 18 (0∙8%) 41 (1∙6%) 0∙0002
Chronic renal failure 26 (1∙2%) 154 (5∙9%) <0∙0001
Chronic obstructive pulmonary disease 512 (23∙3%) 431 (16∙6%) <0∙0001
Asthma 485 (22∙1%) 226 (8∙7%) <0∙0001
Osteoporosis 130 (5∙9%) 192 (7∙4%) 0∙04
Gastro-oesophageal reflux disease 346 (15∙8%) 394 (15∙2%) 0∙6
Solid tumour 17 (0∙8%) 164 (6∙3%) <0∙0001
Disease severity
BSI score 7 (3–10) 6 (4–10) <0∙0001
BSI score risk class
Mild 728 (33∙2%) 753 (29∙0%) 0∙0004
Moderate 674 (30∙7%) 926 (35∙7%)
Severe 793 (36∙1%) 917 (35∙3%)
Radiological status
Reiff score 6 (3–9) 4 (2–6) <0∙0001
Clinical status
Modified Medical Research Council Dyspnoea 
score
2 (1–3) 2 (1–3) 0∙3
Exacerbations in the previous year 1 (0–2) 2 (0–3) <0∙0001
≥1 hospital admission in the previous year 851 (38∙8%) 672 (25∙9%) <0∙0001
Functional status
FEV1 (% predicted) 61∙4 (41∙9–80∙5) 73∙8 (54∙0–92∙1%) <0∙0001
Microbiology
Pseudomonas aeruginosa 301 (13∙7%) 389 (15∙0%) 0∙2
Haemophilus influenzae 11 (0∙5%) 569 (21∙9%) <0∙0001
Staphylococcus aureus 50 (2∙3%) 156 (6∙0%) <0∙0001
Moraxella catarrhalis 22 (1∙0%) 154 (5∙9%) <0∙0001
Enterobacteriaceae 215 (9∙8%) 158 (6∙1%) <0∙0001
Treatment 
Long-term oral antibiotic treatment 271 (12∙3%) 503 (19∙4%) <0∙0001
Inhaled antibiotic treatment 79 (3∙6%) 166 (6∙4%) <0∙0001
Data are median (IQR) or n (%). BSI=Bronchiectasis Severity Index. FEV1=forced expiratory volume in 1 s. *Includes 
patients from Israel.
Table 2: Comparison of patient characteristics between India and Europe
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in a lower­middle­income country. The results show 
the high severity of disease in India as well as the 
striking differences in patient characteristics, aetiology, 
microbiology, and standards of care in India compared 
with Europe and the USA. Key findings include that 
patients in India have more severe bronchiectasis as 
evaluated by prognostic scores. This effect is regardless 
of a younger age, and this increased severity is driven by 
more extensive radiological disease with a remarkably 
high rate of cystic dilatation, and a higher risk of 
admission to hospital for severe exacerbations.
The aetiology of bronchiectasis in India was different to 
that observed in Europe and the USA. Consistent with the 
high prevalence of tuberculosis in the Indian subcontinent, 
tuberculosis was the most frequent underlying cause of 
bronchiectasis and when combined with other severe 
infections, in which infection accounted for 58% of all 
cases of bronchiectasis.23 Lung destruction secondary to 
tuberculosis including bronchiectasis is well described 
and the high background incidence of tuberculosis could 
be one of the explanations for the high frequency of cystic 
bronchiectasis observed in India.23 A systematic review of 
studies that did CT systematically in patients after recovery 
from tuberculosis reported bronchiectasis in 40–80% 
of patients.12 The largest such study, which included 
385 patients with tuberculosis in Blantyre, Malawi, found 
moderate­to­severe bronchiectasis in 44∙2% of scans.13 If 
such findings were translated to India with an estimate of 
2∙8 million cases of tuberculosis per year, the burden of 
bronchiectasis—a lifelong chronic condition—would be 
vast. Bronchiectasis is also thought to be associated with 
severe infections particularly during childhood and a high 
frequency of severe disease including cystic bronchiectasis 
has been reported in indigenous communities with poor 
access to health care.24
Our study identified a relatively high frequency of 
allergic bronchopulmonary aspergillosis in India. 
Strikingly, nearly 50% of patients tested for allergic 
bronchopulmonary aspergillosis had the disease, 
suggesting either a high prevalence or that testing was 
restricted only to those individuals with a very strong 
clinical suspicion of the disorder. Mac Aogáin and 
colleagues19 have recently reported a serological frequency 
of 18% for allergic bronchopulmonary aspergillosis in a 
combined European and Asian cohort with an association 
between sensitisation and frequency of exacerbations.19 
Because allergic bronchopulmonary aspergillosis is a 
treatable cause of frequent exacerbations and lung 
function decline, we recommend increased screening for 
allergic bronchopulmonary aspergillosis in India.
The microbiology data in our study were limited by the 
relatively low rate of sputum sampling observed in 
routine clinical practice in India. Nevertheless, striking 
differences in microbiology were observed with low 
rates of typical pathogens found in Europeans such as 
H influenzae but similar rates of P aeruginosa to Europe 
and the USA.22 Higher rates of Enterobacteriaceae were 
also observed. This observation could reflect differences 
in patient characteristics or environmental conditions 
favouring the growth of certain organisms, including 
community antibiotic use, but the possibility that 
technical factors in microbiological sampling and 
laboratory procedures in India might affect the results 
should also be considered. H influenzae in particular can 
be challenging to isolate and might lose viability after 
delays in processing. Previous studies suggest difficulties 
in isolating H influenzae in low­income and middle­
income countries.25 Further studies are needed to clarify 
this and future studies should ideally include molecular 
analysis and metagenomics, which can overcome some 
of these limitations.
Treatment of bronchiectasis in India was diverse but 
included a high frequency of bronchodilators and inhaled 
corticosteroids.26 In that sense, it could be suggested that 
many patients with bronchiectasis are treated similarly to 
those with COPD, as the majority of patients receiving 
inhaled corticosteroids did not have a history of COPD or 
asthma. This effect might be in part driven by the 
availability of inhaled corticosteroids in India and their 
relatively low cost in a health­care system where patients 
are required to pay for their medications themselves. 
Inhaled corticosteroid use in bronchiectasis is contrary 
to current ERS guidelines. Currently, high­quality 
randomised trials are required to determine whether 
inhaled corticosteroid use has any beneficial effects in 
this patient population.26 One of the most effective and 
least costly interventions for bronchiectasis is airway 
clearance exercises.27 Unfortunately, our data suggests 
these interventions are underutilised in India, in 
common with many health­care systems, with substantial 
variations in care observed between different centres. 
Recent data suggest that airway clearance can cut the 
number of exacerbations and improve quality of life. 
Future studies should examine how the use of airway 
clearance could be increased and optimised.27 Oral and 
inhaled prophylactic antibiotics were also used less 
frequently in India than in other countries. This finding 
is notable as, to date, macrolides are among only a few 
therapies proven to reduce exacerbations.28
We defined risk factors for exacerbations in Indian 
patients and identified some important messages. 
P aeruginosa was strongly associated with a risk of 
exacerbations, confirming airway infection as a key 
treatable trait in India as in Europe and the USA.2,3,6 More 
severe disease reflected by radiology or symptoms were 
also associated with higher exacerbations. The reason 
that being a male patient was associated with more 
exacerbations than being a female patient even after 
adjustment for other factors is intriguing and requires 
further study. Even after adjustment for confounders, a 
history of pulmonary tuberculosis was associated with 
more frequent exacerbations in this population, which 
suggests that tuberculosis might be an important 
contributor to the high severity of disease that we 
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observed in the Indian context. We observed that the 
number of exacerbations treated with oral antibiotics was 
relatively low in India, whereas admission to hospital 
due to exacerbations was more common in India than in 
Europe and the USA. This finding might reflect health­
care system organisation that is more skewed towards 
hospital­based care, but might also reflect differences in 
severity of disease and therefore risk of more severe 
exacerbations. It is intriguing that a recent phase 3 trial 
of inhaled dry powder ciprofloxacin, which was done in 
eastern European countries with a high frequency of 
tuberculosis, also reported very low frequencies of 
moderate exacerbations, even in a population with a 
history of two more exacerbations in the past, and quality 
of life scores suggesting a high burden of symptoms.8,9
Our work nevertheless confirms that bronchiectasis in 
Asian patients frequently follows an aggressive course 
with onset at an earlier age, more extensive lung damage, 
and severe symptoms compared with populations in 
Europe and the USA. Similar data from China support 
that this finding is not unique to India.4 Severity of 
disease assessment tools such as the Bronchiectasis 
Severity Index were derived and validated predominantly 
in populations in developed countries.18 We found nearly 
all of the components of these scores, including 
age, radiology, microbiology, functional status, and 
exacerbations were markedly different in India compared 
with the countries where the Bronchiectasis Severity 
Index and equivalent scores were developed. Such tools 
should be used with caution in Asian populations and 
specific disease severity tools for these patients might be 
required.
Our work suggests the need for caution in interpreting 
the results of bronchiectasis studies arising from 
different geographical regions.29 Patients in India were 
markedly different from those reported in other 
countries. Consequently, the results of trials or cohort 
studies in Europe, USA, or Australasia might not be 
applicable to very different patients in India or elsewhere. 
This discrepancy suggests the need to do studies in 
different patient populations and to carefully phenotype 
patients. It also suggests the need for care in selecting 
patients for randomised trials.
Our work should serve as a baseline for efforts to 
improve the quality of care for bronchiectasis in India. 
The study nevertheless has limitations. These initial 
results are cross­sectional and ongoing data collection in 
the registry will allow studies into lung function decline 
and long­term mortality.30 The study did not collect data 
for household biomass exposure, which might be 
important in respiratory morbidity in the region. Some 
aspects of our epidemiological data are limited by the 
quality of care; underuse of aetiological testing, which 
leads to more patients being classified as idiopathic or 
post­infective; and the microbiological data, which are 
likely to underestimate the frequency of chronic infection 
because of inadequate sputum sampling. Nevertheless, 
the strength of the data reflect what clinicians will 
encounter in daily practice.
In conclusion, we present unique epidemiological data 
for bronchiectasis in India that will be important to 
inform quality improvement efforts in India as well as 
future clinical trial design and disease understanding.
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